Biomedical subjects

J Riggert

Publications and source records attributed to J Riggert.

38 records · Page 3Linked to original sources

PubMed1994

[Platelet membrane glycoproteins in thrombocytapheresis and platelet concentrates].

Membrane glycoprotein (GP) expression on platelets changes during preparation of concentrates and storage. Recent studies proved that the increased expression of the GMP-140 (CD 62), a GP appearing on platelets after activation, correlates with the in vivo recovery of transfused platelets. We therefore investigated the expression of this and three other GP (GP IIb/IIIa, GP, Ib, GP 53), detected by flow cytometry, in normal controls and in platelet concentrates prepared by four different methods (apheresis, preparation from buffy coat, from pooled buffy coat and platelet-rich plasma) after preparation and during storage. Furthermore we investigated the influence of filtration, radiation and washing platelet concentrates on the expression of GP. The results can be summarized as follows: (1) The mean surface fluorescence (MF) is a better parameter for the evaluation of preparation and storage lesions than the total number of positive cells. (2) The mean fluorescence of GP Ib in platelet concentrates is generally lower than in normal controls and decreases continuously during storage; there is a small loss of GP Ib through washing and filtration. (3) GP IIb/IIIa fluctuates during preparation and storage, therefore it is not suitable for evaluation of quality. (4) The percentage of CD 62 positive cells and their mean fluorescence is higher in platelet concentrates than in normal controls and increases during storage continuously. There is a weak correlation of CD 62 with CD 63. (5) The changes of GP in apheresis concentrates and concentrates obtained from whole blood are similar after preparation and during storage.

Blood Platelets↗

PubMedDate not supplied

Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer.

BACKGROUND: Women with breast cancer and > 10 positive lymph nodes have an unfavorable prognosis. The optimal combination and intensity of adjuvant chemotherapy is uncertain. Between July 1994 and December 1996 we treated 19 patients with early intensive followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation. PATIENTS AND METHODS: Patients were initially diagnosed with breast cancer and multiple positive lymph nodes. Induction chemotherapy consisted of two courses VP16, ifosphamide, cisplatin and epirubicin (VIPE) and one course of mitoxantrone, cyclophosphamide and thiotepa (MCT). Peripheral blood stem cells were mobilized after the first or second course of VIPE and retransfused two days after high dose chemotherapy. RESULTS: Stem cells were successfully collected in all patients. Major toxicities (WHO grade III and IV) were neutropenia, thrombocytopenia, alopecia, nausea, infections and mucositis. Hematopoietic recovery occurred in all patients with a median of 10 days for leukocytes and 13 days for platelets. No patient died of therapy-induced complications. The median observation time is 24 months. Two patients have relapsed, one with locoregional disease. The projected rate of patients with disease-free survival after three years is 88%. CONCLUSIONS: Early intensive and myeloablative chemotherapy followed by peripheral blood stem cell transplantation is a highly efficient and feasible protocol for high risk patients with breast cancer.

Adolescent↗